Scientists dig into rare blood cancer to unlock better care
NCT ID NCT04411043
First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 3 times
Summary
This study gathers information from 50 people with T-cell prolymphocytic leukemia (T-PLL), a rare and aggressive blood cancer. Researchers will look at patients' medical records, lab results, and genetic data to better understand the disease and how it responds to current treatments. No new drug is being tested; the goal is to improve future care by learning from past and present cases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better understand T-PLL and improve how they manage the disease.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly test a new therapy or cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROLYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chd Le Mans
RECRUITINGLe Mans, 72000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug combo aims to tackle tough lymphoma
- New transplant recipe aims to tame Graft-Versus-Host disease
- New drug combo aims to make stem cell transplants safer for blood cancer patients
- Massive T-Cell lymphoma database aims to unlock new insights
- Blood cancer transplant study tests safer GVHD prevention
- Engineered donor cells take aim at tough blood cancers in early trial